Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04042740 |
Recruitment Status :
Active, not recruiting
First Posted : August 2, 2019
Last Update Posted : February 4, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatitis C Infection HIV Infection | Drug: Glecaprevir/Pibrentasvir (G/P) Drug: Ribavirin (RBV) | Phase 2 |
The study will be conducted in two steps. In Step 1, participants will receive four weeks of treatment with G/P for acute HCV infection and then followed 24 weeks post treatment. Participants with HCV recurrence (reinfection, suspected relapse or undefined post-treatment viremia) or HCV virologic failure before or at the Step 1 Week 16/SVR12 (sustained virologic response 12 weeks post-treatment) visit may enter Step 2 for re-treatment. The remaining participants complete the study at Week 28 of Step 1. The study primary and secondary outcome measures pertain to Step 1.
In Step 2, participants will be re-treated with G/P with or without ribavirin (RBV) for up to 16 weeks, and followed for 24 weeks post treatment. Post-treatment follow-up for Step 2 will include visits for SVR12 determination after re-treatment.
In Step 1, study visits are scheduled at study entry, weeks 1 and 2 (on-treatment), week 4 (treatment discontinuation), and weeks 8, 12, 16 and 28 (post-treatment follow-up). In Step 2, participants will have study visits during the re-treatment period, where the number of visits depends on the re-treatment, and visits at 12 and 24 weeks post treatment. Study visits may include physical examinations, clinical assessments, blood and urine collection, questionnaires, and HCV re-infection prevention counseling.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C) |
Actual Study Start Date : | November 15, 2019 |
Estimated Primary Completion Date : | April 30, 2022 |
Estimated Study Completion Date : | October 31, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Glecaprevir/Pibrentasvir (G/P)
In Step 1, participants will receive G/P FDC tablets to be taken orally once daily for 4 weeks. Any participant who experiences viral re-infection, suspected relapse, virologic failure, or undefined post-treatment HCV viremia may enter Step 2. In Step 2, participants may receive G/P FDC tablets orally once daily for 8-16 weeks. Some participants may also receive ribavirin (RBV) tablets orally twice daily. Alternate regimens are allowed in Step 2. |
Drug: Glecaprevir/Pibrentasvir (G/P)
Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally. Drug: Ribavirin (RBV) Tablets containing 200 mg of ribavirin. RBV dosed according to weight-based and renal dosing tables in study protocol. |
- Proportion of participants with sustained virologic response at 12 weeks post-treatment (SVR12) [ Time Frame: Week 16 (12 weeks post treatment) ]SVR12 defined as achieving unquantifiable HCV RNA (less than the lower limit of quantification [LLOQ] target detected [TD] or target not detected [TND]) at study visit 12 weeks post treatment. If a participant does not have any HCV RNA measurements in this time period then the participant will be considered as SVR12 failure, unless there are preceding and subsequent HCV RNA measurements that are both LLOQ (either TD or TND).
- Proportion of participants who experienced adverse events (AEs) [ Time Frame: From study treatment initiation to 4 weeks after study treatment discontinuation (Week 8) ]Study protocol required reporting of (1) AEs Grade greater than or equal to 2, (2) AEs that led to a change in study treatment regardless of grade and (3) AEs meeting ICH definition of SAE or Expedited AE (EAE) reporting requirement. DAIDS AE Grading Table (V2.1) and DAIDS EAE Manual (V2.0) are used.
- Number of participants who complete 4 weeks of treatment without discontinuation due to AEs [ Time Frame: From study entry to Week 4 ]
- Proportion of participants with HCV RNA less than LLOQ (TD or TND) [ Time Frame: Weeks 1, 2, 4, 8, 12, 28 ]
- Number of participants with HCV virologic failure [ Time Frame: Weeks 1, 2, 4 ]Virologic failure defined as failure to achieve unquantifiable HCV RNA and confirmed increase in HCV RNA greater than 1 log10 from on-treatment nadir

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
- Acute HCV infection (or reinfection) within 24 weeks prior to entry.
- Detectable HCV RNA at the screening visit.
Exclusion Criteria
- Any HCV treatment during the current acute HCV infection episode.
- Known preexisting cirrhosis
- Acute HIV-1 infection
- Presence of active or acute AIDS-defining opportunistic infections, active serious infection (other than HIV-1 or HCV), active hepatitis B virus (HBV) or active hepatitis A virus (HAV)
- Chronic use of systemically administered immunosuppressive agents
- History of solid organ transplantation.
- History of conditions that could interfere with the absorption of the study drug.
- Concurrent use of prohibited medications
- Known hypersensitivity to glecaprevir or pibrentasvir, the metabolites, or parts of the formulation.
- Females who are pregnant or breastfeeding
- Males with pregnant female partner.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04042740
United States, California | |
Ucsd, Avrc Crs (701) | |
San Diego, California, United States, 92103 | |
United States, Massachusetts | |
Massachusetts General Hospital ACTG CRS (101) | |
Boston, Massachusetts, United States, 02114 | |
United States, North Carolina | |
Unc Aids Crs (3201) | |
Chapel Hill, North Carolina, United States, 27514 | |
United States, Rhode Island | |
The Miriam Hosp. ACTG CRS (2951) | |
Providence, Rhode Island, United States, 02906 |
Study Chair: | Arthur Y. Kim, MD | Massachusetts General Hospital (MGH) CRS | |
Study Chair: | Susanna Naggie, MD, MHS | Duke University Medical Center CRS | |
Study Chair: | David Wyles, MD | University of Colorado Hospital CRS |
Responsible Party: | AIDS Clinical Trials Group |
ClinicalTrials.gov Identifier: | NCT04042740 |
Other Study ID Numbers: |
ACTG A5380 38553 ( Registry Identifier: DAIDS-ES Registry Number ) UM1AI068636 ( U.S. NIH Grant/Contract ) |
First Posted: | August 2, 2019 Key Record Dates |
Last Update Posted: | February 4, 2021 |
Last Verified: | February 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Individual participant data that underlie results in the publication, after deidentification. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
Time Frame: | Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH. |
Access Criteria: |
|
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Acute Hepatitis C Infection Glecaprevir Pibrentasvir 4 weeks Direct-acting antivirals |
Infection Communicable Diseases Hepatitis A Hepatitis C Virus Diseases Hepatitis Liver Diseases Digestive System Diseases Hepatitis, Viral, Human |
Enterovirus Infections Picornaviridae Infections RNA Virus Infections Flaviviridae Infections Ribavirin Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents |